Skip to Main Content

Paper Details

Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data.
JCO Oncol Pract
5
2024
Author NameAffiliation
Jochen K LennerzMassachusetts General Hospital/Harvard Medical School
  • 1 - 1

Datasets

Release 1.2